

# Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes

Schulz, Eduard; Aplan, Peter D.; Freeman, Sylvie D; Pavletic, Steven Z

DOI:

[10.1182/bloodadvances.2023010098](https://doi.org/10.1182/bloodadvances.2023010098)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Schulz, E, Aplan, PD, Freeman, SD & Pavletic, SZ 2023, 'Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes', *Blood Advances*. <https://doi.org/10.1182/bloodadvances.2023010098>

[Link to publication on Research at Birmingham portal](#)

## General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

## Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes

Tracking no: ADV-2023-010098R1

Eduard SCHULZ (Myeloid Malignancies Program, National Institutes of Health, Bethesda MD 20892, United States) Peter Aplan (Myeloid Malignancies Program, National Institutes of Health, Bethesda MD 20892., United States) Sylvie Freeman (University of Birmingham, UK, United Kingdom) Steven Pavletic (Myeloid Malignancies Program, National Institutes of Health, Bethesda MD 20892., United States)

### Abstract:

Approximately 90% of patients with myelodysplastic syndromes (MDS) have somatic mutations in the malignant cells that are known or suspected to be oncogenic. The genetic risk-stratification of MDS has evolved substantially by the introduction of the clinical-molecular International Prognostic Scoring System (IPSS-M) that establishes next-generation sequencing at diagnosis as a standard of care. Furthermore, the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias has refined MDS diagnostic criteria with the introduction of a new myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) category. Monitoring measurable residual disease (MRD) has historically been used to define remission status, improve relapse prediction, and determine the efficacy of antileukemic drugs in patients with acute and chronic leukemias. However, in contrast to leukemias, assessment of MRD including tracking of patient-specific mutations has not yet been formally defined as a biomarker for MDS. This article summarizes current evidence and challenges, and provides a conceptual framework for incorporating MRD into the treatment of MDS and future clinical trials.

**Conflict of interest:** COI declared - see note

**COI notes:** E.S.: Amgen (Honoraria). P.D.A.: No conflict of interest. S.Z.P.: No conflict of interest.

**Preprint server:** No;

**Author contributions and disclosures:** Conception of the work: E.S., S.Z.P; Interpretation of Data: E.S., S.F., P.D.A., S.Z.P; Drafted the manuscript: E.S., S.F., P.D.A., S.Z.P. All authors have seen and approved the manuscript being submitted.

**Non-author contributions and disclosures:** No;

**Agreement to Share Publication-Related Data and Data Sharing Statement:** N/A

**Clinical trial registration information (if any):**

# Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes

## Short title

MRD in MDS

## Authors and affiliations

Eduard Schulz<sup>1,2</sup>, Peter D. Aplan<sup>1,2</sup>, Sylvie Freeman<sup>3</sup>, Steven Z. Pavletic<sup>1,2</sup>

<sup>1</sup>Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

<sup>2</sup>Myeloid Malignancies Program, National Institutes of Health, Bethesda MD 20892.

<sup>3</sup>Department of Clinical Immunology, Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, UK.

## Author contributions

All authors researched the data for the article and made a substantial contribution to the discussion of the content. ES wrote the first draft, and all authors reviewed and edited the manuscript before submission.

## Disclaimer

The views expressed in this work do not represent the official views of the National Institutes of Health or the United States Government.

## Key words

Myelodysplastic syndrome; measurable residual disease; acute myeloid leukemia; stem cell transplantation; response criteria.

## Correspondence

Steven Pavletic, M.D., M.S.  
Senior Clinician, Head, Graft-versus-Host and Late Effects Section  
Clinical Director, Myeloid Malignancies Program  
National Cancer Institute, Center for Cancer Research  
National Institutes of Health, 10 Center Drive, Room CRC 4-3130  
Bethesda, MD 20892-1907  
Phone: 301-204-9702  
Email: [pavletis@mail.nih.gov](mailto:pavletis@mail.nih.gov)

1 **Manuscript Data**

2 Word counts

3 Abstract – 160

4 Text – 5163

5 Figures – 2

6 Tables – 2

7 Supplemental material – 4 Tables

8 References – 118

9

**10 Abstract**

11 Approximately 90% of patients with myelodysplastic syndromes (MDS) have somatic mutations  
12 in the malignant cells that are known or suspected to be oncogenic. The genetic risk-  
13 stratification of MDS has evolved substantially by the introduction of the clinical-molecular  
14 International Prognostic Scoring System (IPSS-M) that establishes next-generation sequencing  
15 at diagnosis as a standard of care. Furthermore, the International Consensus Classification  
16 (ICC) of myeloid neoplasms and acute leukemias has refined MDS diagnostic criteria with the  
17 introduction of a new myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) category.  
18 Monitoring measurable residual disease (MRD) has historically been used to define remission  
19 status, improve relapse prediction, and determine the efficacy of antileukemic drugs in patients  
20 with acute and chronic leukemias. However, in contrast to leukemias, assessment of MRD  
21 including tracking of patient-specific mutations has not yet been formally defined as a biomarker  
22 for MDS. This article summarizes current evidence and challenges, and provides a conceptual  
23 framework for incorporating MRD into the treatment of MDS and future clinical trials.

24

## 25 **Introduction**

26 Measurable residual disease (MRD), the detection of residual malignant cells during  
27 complete hematologic remission, allows for disease monitoring and is the most important  
28 predictor of survival for acute leukemias.<sup>1-3</sup> Although myelodysplastic syndromes (MDS) are  
29 considered malignant preleukemic myeloid neoplasms and may share many features with  
30 subtypes of acute myeloid leukemia (AML), MRD has not yet been effectively applied as a  
31 biomarker in MDS.<sup>4-8</sup>

32 MDS are a heterogeneous group of biologically and clinically distinct sub-entities  
33 characterized by ineffective and dysplastic hematopoiesis; therefore, standardizing clinical  
34 response criteria has been difficult.<sup>8</sup> The most recently proposed International Working Group  
35 (IWG) 2023 response criteria for higher risk MDS is the first to consider MRD status as an  
36 exploratory endpoint and recommends its reporting as a response category.<sup>9</sup> However, the IWG  
37 2023 criteria do not provide details about the application of MRD testing or a formal definition of  
38 MRD response.

39 The available evidence shows that MRD assessment in MDS is likely to be context-  
40 dependent and influenced by biological and clinical prognostic factors like genetic subtype,  
41 disease stage, and treatment strategy. Furthermore, analytical performance and applicability  
42 (subgroup versus general testing) of diagnostic tests as well as timepoints and sample sources  
43 are important and must be considered in the assessment of MRD in MDS. Widespread  
44 implementation of MRD diagnostics in MDS is currently limited by cost and proven clinical utility.

45 We propose that MRD can be an important biomarker in MDS, which would allow for  
46 pharmacodynamic assessment, prediction of survival, disease monitoring and treatment  
47 decision making. In this manuscript, we will first review methodologic considerations, such as  
48 multiparametric flow cytometry (MFC) versus next generation sequencing (NGS) as well as bone  
49 marrow (BM) versus peripheral blood (PB) as source material. We will next consider MRD in the

50 context of clonal hematopoiesis (CH) and for the different clinical settings of non-intensive  
51 treatment of older or frail MDS patients, and allogeneic hematopoietic cell transplantation (HCT).  
52 Finally, we will consider open questions and prospects for the future, including emerging  
53 technologies and efforts toward standardization of MRD evaluation.

## 54 **Methodologic Considerations**

### 55 **Multiparametric Flow Cytometry or Next Generation Sequencing**

56 MFC-MRD, which is considered technically difficult to standardize but has a short  
57 turnaround time, quantifies MRD as progenitor cells that express a leukemia-associated or  
58 different from normal aberrant immunophenotype (LAIP/DfN), identified in approximately 90% of  
59 AMLs but probably less frequently in MDS.<sup>3,10</sup> MFC-MRD has a limit of detection (LOD) of 0.1%  
60 to 0.01% ( $10^{-3}$  to  $10^{-4}$ ) although higher sensitivities ( $10^{-5}$  to  $10^{-6}$ ) are reported for leukemic stem  
61 cell (LSCs) detection by immunophenotypic aberrant hematopoietic stem cell populations.<sup>11</sup>  
62 MFC assessment of different from normal 'dysplastic' maturation<sup>12-14</sup> could supplement MFC-  
63 MRD quantitation of aberrant blast or stem cells (**Figure 1**).<sup>15</sup> However interpretation of MFC-  
64 MRD in MDS may be limited by residual CH-related changes of hematopoietic cells as well as  
65 the challenge of discriminating between lower risk dysplastic clones and leukemic blasts.<sup>16,17</sup>

66 MFC has been used as an MRD test for MDS in a few studies that included high-risk  
67 MDS patients in older AML cohorts.<sup>16,18</sup> Evidence from non-intensive treatment trials in AML  
68 patients ineligible for HCT shows a significantly higher relapse risk for MFC-MRD positive  
69 patients.<sup>19-22</sup> In the peri-transplant setting, tracking of leukemic blasts could be accomplished by  
70 MFC-MRD,<sup>23,24</sup> but few studies have examined this approach outside of AML treatment.<sup>25-28</sup>

71 The genetic landscape of MDS has been studied and reviewed in detail by several  
72 authors.<sup>7,29-32</sup> About 90% of MDS patients will have at least one oncogenic lesion but no single  
73 mutation is pathognomonic for MDS.<sup>29,30,32</sup> As recurrent hotspot mutations and gene fusions that  
74 are detectable by real-time quantitative polymerase chain reaction (qPCR) are less frequent in

75 MDS compared to AML, an alternate approach, such as targeted error-corrected NGS is  
76 possibly the most useful method for MRD assessment in MDS.<sup>6,32-36</sup> However, no single MRD  
77 method has perfect sensitivity and specificity in MDS.

78 NGS-MRD also has several known limitations that have to be addressed prior to broader  
79 application in MDS.<sup>37</sup> From a technological perspective, the two most important limitations are  
80 the standardization of the bioinformatics analysis platform and the intrinsic error rate due to rare  
81 events in a given sample interfering with the clear discrimination of the target from noise.<sup>3,36</sup> Due  
82 to its intrinsic error rate, conventional NGS now commonly used at diagnosis of MDS/AML has a  
83 LOD of about 2% to 5% variant allele frequency (VAF).<sup>35,36</sup> Although a positive MRD test result  
84 above this LOD during complete remission (CR) could be useful prognostically, a deeper LOD is  
85 needed to give a meaningful discrimination of relapse risk between positive and negative tests in  
86 most instances. Technical advancements like molecular tagging (unique molecular identifiers,  
87 UMI) and duplex sequencing allow for error-correction leading to LODs far below 0.1% that are  
88 mainly determined by the amount of input DNA/ number of cells and costs.<sup>35,36</sup>

89 From a biological point of view, results of NGS-MRD do not provide the full picture of  
90 MDS/AML defined by clonal diversity and evolution with sometimes indetermined potential due  
91 to CH (**Figure 2**).<sup>38-40</sup> Consequently, distinguishing between residual hematopoietic stem cells  
92 (HSCs) carrying clonal mutations of no pathogenic significance and LSCs by NGS-MRD is  
93 challenging. Furthermore, the ability of tracking MRD by NGS is also limited in MDS with  
94 germline predisposition when no additional genetic markers are present because germline  
95 mutations are noninformative for MRD (**supplementary Table 1**).<sup>3-5</sup> Fundamentally, two  
96 approaches of target selection in NGS-MRD can be distinguished – sequencing of predefined  
97 target panels versus patient-specific mutation monitoring, but to date it is unknown which  
98 approach is superior. This is a moving target, and the decision will depend on a fine balance  
99 between costs versus additionally acquired information and evidence related to outcome benefit.



**100 Source Material: Bone Marrow or Peripheral Blood**

101 Studies in AML patients demonstrated a comparable clinical impact of MRD testing  
102 between PB and BM aspirate specimens.<sup>41-45</sup> PB as a source for MRD testing may be more  
103 suitable than BM in MDS because PB is generally more informative about CH, is not affected by  
104 dilution or fibrosis, and is more easily accessible thereby showing greater consistency in addition  
105 to lower cost for serial examinations. However, sensitivity is considered to be about 1 log lower  
106 in PB and there are concerns about the accurate quantification of the myeloid clonal burden  
107 during phases of neutropenia and concurrent relative lymphocytosis.<sup>3,46</sup> MRD testing is most  
108 useful in patients who reach complete remission (CR) and show no morphological signs of the  
109 underlying disease. However, in cases where patients do not recover hematopoiesis due to drug  
110 toxicity or limited stem cell reserve, skewed lymphoid to myeloid cells ratio may be a relevant  
111 problem.<sup>46</sup> In a research context, precise calculations of VAF of somatic mutations could be  
112 crucial for monitoring the pharmacodynamics of new drugs in refractory patients who fail to  
113 achieve CR. Until prospective studies confirm that PB can effectively replace BM in MRD testing  
114 for MDS and that both molecular and flow cytometric testing yield comparable results in PB, BM  
115 should continue to be regarded as the current gold standard. Circulating cell-free tumor DNA  
116 could provide an alternative MRD target in PB during the phase of neutropenia.<sup>47,48</sup>

117 The European LeukemiaNet (ELN) MRD working party actively pursues the goal of  
118 standardization and published a detailed consensus document in 2021 updating the  
119 recommendations on MRD in AML.<sup>3,49</sup> The currently recommended MRD threshold that has  
120 been established by prospective trials for AML in first CR is 1 in 1,000 cells (0.1%;  $10^{-3}$ ). We  
121 propose that the ELN MRD recommendations on optimized technical requirements, minimal  
122 detection limit and standardized reporting should also be implemented in the MRD assessment  
123 of MDS (**supplementary Table 1**).

124 **Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined**  
125 **Significance**

126 The prevalence of CH is generally age-related and its detection is assay dependent.<sup>50-52</sup>  
127 When sensitivity of sequencing reaches approximately 1% VAF, 85% of persons with an age of  
128 80 years or older will have age-related CH.<sup>53</sup> CH of indeterminate potential (CHIP), defined by  
129 somatic mutations with a VAF of 2% or higher, and clonal cytopenia of undetermined  
130 significance (CCUS), defined by CHIP with persistent cytopenia, are potentially preneoplastic  
131 states and inherent features in the pathogenesis of MDS.<sup>4,5,53-55</sup> However, the occurrence of  
132 somatic mutations in CH, CHIP and CCUS are stochastic events and the kinetics of clone  
133 growth leading to progression to MDS/AML is unpredictable in most cases (**Figure 2**).<sup>38-40,56-58</sup>  
134 Complicating matters, copy number alterations, independently or co-occurring with single  
135 nucleotide variants, have also been shown to play an important role in leukemogenesis.<sup>59,60</sup>

136 The number, combinations and VAFs of somatic mutations show a strong association  
137 with progression from CCUS to myeloid neoplasm.<sup>38,50,61-63</sup> CH is a risk factor for therapy-related  
138 myeloid neoplasms in patients who received cytotoxic treatment for primary malignancies.<sup>64-67</sup>  
139 CH involving somatic mutations in *TP53* and *PPM1D* is common in patients developing therapy-  
140 related MDS.<sup>65,67-69</sup> Recent evidence suggests that also thalidomide analogs like lenalidomide  
141 provide a growth advantage to *TP53* mutated hematopoietic stem cells (HSCs).<sup>67</sup> Longitudinal  
142 measurements of mutant driver genes and clone size may allow for early identification of  
143 progression into MDS. However, there is currently insufficient evidence to suggest that  
144 monitoring of CH or CCUS could be beneficial for high-risk populations such as individuals with  
145 somatic *TP53* mutations that received cytotoxic therapy. Reduction in cost and further  
146 improvements in sequencing and data analyses could lead to clone-specific targeted  
147 interventions as part of a secondary prevention.

148 Studies in AML and MDS patients suggest that persistence of CH, especially somatic  
149 mutations in one or more of the *DTA* (*DNMT3A*, *TET2*, *ASXL1*) genes, during CR after  
150 chemotherapy or before HCT is not associated with increased risk of relapse.<sup>3,70-73</sup> It is important  
151 to bear in mind that only AML entities that are characterized by certain driver mutations (*NPM1*,  
152 bZIP in-frame mutated *CEBPA*) or gene fusions (*CBFB::MYH11*, *RUNX1::RUNX1T1*) are  
153 typically cured without allogeneic HCT, presumably because their LSCs are chemotherapy-  
154 sensitive.<sup>49</sup> AML with adverse risk genetic abnormalities including mutated *TP53* and  
155 myelodysplasia-related gene mutations or cytogenetic abnormalities, whether primary or  
156 secondary, should receive HCT as part of their therapy.<sup>49</sup> Recipient's CH should disappear after  
157 HCT which can be tracked by MRD testing but the timepoint at which residual *DTA* mutations  
158 should not be detected after transplantation is not established.<sup>42,47,74,75</sup> Additionally, donor-  
159 derived CH must be carefully excluded especially if untargeted NGS is used for MRD monitoring.  
160<sup>76,77</sup> A retrospective NGS-MRD study of 131 AML patients who underwent HCT showed that  
161 residual *DTA* mutations had no prognostic significance at day 90 and day 180 after HCT.<sup>71</sup> This  
162 study indicated that kinetics — an increase in VAF of *DTA* mutations between two timepoints —  
163 may be a better prognosticator of relapse.<sup>78</sup> In the future, serial single-cell sequencing analyses  
164 will likely provide an answer to which mutations or combinations of mutations of residual CH  
165 have an impact on clinically relevant endpoints.<sup>79,80</sup>

## 166 **Clinical Considerations**

167 Adapting the MRD assessment approach based on treatment goals together with  
168 considerations of cost and inconvenience is reasonable. Since effective treatment options are  
169 currently lacking for most MDS patients who are not eligible for HCT, MRD testing may not be  
170 justified for the majority of "real world" patients receiving palliative treatment outside of clinical  
171 trials. The subsequent sections will explore various clinical scenarios that may have different  
172 implications for MRD results.

**173 Non-intensive Treatment of MDS**

174 Cytogenetic response, a complete or partial disappearance of chromosomal  
175 abnormalities, was introduced as a response criterion for MDS by the IWG in 2000 to enable  
176 prospective evaluation and comparability between clinical trials although no data were available  
177 at that time to support a relationship between cytogenetic response and clinical outcome.<sup>81</sup>  
178 Since then, most clinical trials that have included cytogenetic response criteria as an endpoint  
179 have demonstrated this association.<sup>8</sup> We argue that defining MRD criteria for MDS is necessary  
180 for the same reasons that cytogenetic response criteria were established, to ensure successful  
181 clinical research and clear comparisons between trials.

182 Regular MRD assessment of MDS patients who are not transplant eligible should  
183 currently be focused on clinical research. With the exception of hypoplastic MDS or MDS with  
184 less than 5% BM blasts and isolated 5q deletion (MDS-del[5q]), treated with immunosuppressive  
185 agents or lenalidomide, respectively, most patients with low-risk MDS will initially receive  
186 supportive care when they need treatment because of cytopenia.<sup>7</sup>

187 We advocate that reporting MRD responses is important for understanding the efficacy of  
188 investigational new drugs. One example is the phase 2 portion of the MDS3001 study, which  
189 evaluated the efficacy of imetelstat, a competitive inhibitor of telomerase activity, in 57 red blood  
190 cell (RBC) transfusion-dependent patients with lower-risk MDS.<sup>82</sup> Treatment with imetelstat  
191 resulted in a clinically meaningful 37% reduction in the 8-week RBC transfusion dependence  
192 rate. It should be emphasized here that the reduction of the VAF of somatic *SF3B1* mutations  
193 correlated with transfusion independence suggesting that *SF3B1* VAF could be a surrogate  
194 molecular marker that predicted response (prolonged transfusion independence).

195 Residual mutations of CH further complicate MRD analysis following non-intensive  
196 therapies because they represent the remaining founder clone with residual hematopoietic  
197 potential that cannot be eradicated without the use of HCT thus far.<sup>39,83</sup> An improvement in

198 treatment efficacy targeting culprit subclones would make MRD testing more attractive as a  
199 surrogate marker for PFS. Since it is biologically implausible that increasing VAF of mutations  
200 paralleling progression of subclones would not influence critical outcomes,<sup>84</sup> incorporating MRD  
201 analysis in response criteria and in definitions of progressive disease seems to be a reasonable  
202 goal.

203 This premise would also apply to future drugs with a mechanism of action that causes  
204 differentiation of neoplastic cells into normal blood cells instead of eradication, thereby improving  
205 suboptimal hematopoiesis but potentially not leading to a reduction in clonal burden. Only after  
206 studying such associations we can learn about the role of MRD and clinical benefit.  
207 Consequently, MRD assessment should be incorporated into the design of clinical trials  
208 investigating new agents for the treatment of MDS, while implementing recommendations of the  
209 US Food and Drug Administration on regulatory considerations for the use of MRD as a  
210 surrogate efficacy end point.<sup>85</sup>

211 HSCs with del(5q) are selectively resistant to lenalidomide. Tehranchi et al. showed that,  
212 similar to a molecular MRD measurement, the 5q deletion remained detectable in all patients  
213 with MDS-del(5q) by fluorescence in situ hybridization of sorted CD34+, CD38-/low, CD90+  
214 HSCs at the time of CR during lenalidomide treatment, even in patients with complete  
215 cytogenetic response (CCyR).<sup>86</sup> A retrospective analysis of the phase 2 MDS-003 and the  
216 phase 3 MDS-004 studies showed that 103/181 (57%) patients achieved a cytogenetic response  
217 with lenalidomide of whom 84/103 (81.6%) also achieved RBC transfusion independence at  $\geq 26$   
218 weeks.<sup>87</sup> The case of lenalidomide and MDS-del(5q) is a good example demonstrating that  
219 MRD testing on the one hand shows the efficacy of specific treatment at the genetic level and on  
220 the other hand provides evidence that a cure in the strict sense is not possible because the  
221 malignant stem cell is not eradicated.

222 Patients with low-risk MDS-del(5q) who are treated with lenalidomide have a median  
223 AML-free survival of approximately 3.5 years.<sup>87</sup> Transplant eligible patients may benefit from  
224 early detection of subclonal *TP53* mutations at diagnosis and regular monitoring during  
225 lenalidomide treatment.<sup>67,88-91</sup> In a prospective multicenter study of the German MDS study  
226 group involving 67 MDS-del(5q) patients, median overall survival (OS) was significantly different  
227 between patients with (N=59) and without (N=8) a *TP53* mutation at diagnosis (3.55 years  
228 versus not reached; P=0.002).<sup>89</sup> As the expansion of a *TP53* subclone is associated with  
229 treatment failure and progression during treatment with lenalidomide, *TP53* MRD testing would  
230 allow better stratification of patients for early HCT or clinical trials.<sup>90</sup>

231 High-risk MDS is treated with hypomethylating agents (HMA) and response is associated  
232 with the number and type of somatic mutations.<sup>43,84,92-95</sup> The decrease in VAF of certain high-risk  
233 or clearly transforming mutations indicating partial or complete elimination of subclones is  
234 associated with better PFS after treatment with HMAs such as azacitidine or decitabine, alone or  
235 in combination with other drugs, in several cohort studies (**Table 1; supplementary Table 2**).  
236 There seems to be a strong concordance between molecular and clinical responses but the  
237 exact threshold of mutation clearance indicating highest outcome difference during treatment  
238 with HMAs is not known. VAF thresholds of 1% and 5% have been described to be meaningful  
239 in this setting and have to be put in context of baseline risk groups such as *TP53*.<sup>83,84,96</sup>

240 Treatment response is usually short-lived with currently available agents, which may  
241 explain why MRD assessment has not been useful in the palliative setting of high-risk MDS in  
242 routine care. However, this does not mean that MRD assessment has no merit, but may instead  
243 indicate that the current therapeutic options for MDS are limited. What would it mean if HMA  
244 therapy did not lead to a temporary suppression of *TP53* mutated clones?<sup>84,92,94,96-99</sup> The answer  
245 is that such a therapy would be less effective and bridge fewer patient with MDS/AML to HCT  
246 which is the only chance for cure.<sup>84,94,100-102</sup>

**247 Pre-transplant Setting: Prognostication and Treatment Decision Making**

248 Evidence has emerged indicating that MDS with 10% to 19% BM blasts shares important  
249 biological and clinical similarities with AML when entities are stratified by genetics.<sup>5,6</sup> Many  
250 studies that investigated the role of MRD in AML included a subgroup of MDS/AML, which  
251 allowed basic principles of MRD analysis to be applied to results of studies that enrolled AML  
252 patients as majority (**Table 1; supplementary Table 2**).<sup>16,18,23,70,103</sup> The creation of the new  
253 entity MDS/AML in the recently published International Consensus Classification (ICC) has  
254 introduced facts that affect the care of many MDS patients outside of clinical trials.<sup>5</sup> It is a reality  
255 that many academically affiliated transplant centers will use available MRD technologies,  
256 including less sensitive conventional techniques, in individual cases with the intent to improve  
257 the survival of their transplant-eligible MDS patients. Ideally, MRD measurements should be  
258 performed in special reference laboratories.

259 When non-intensive or intensive treatments are used as a bridge to HCT, pre-transplant  
260 MRD assessment can provide valuable prognostic information to influence the conditioning  
261 regimen and the post-transplantation plan.<sup>26</sup> Many retrospective studies have evaluated the  
262 prognostic impact of somatic mutations at the time of HCT on the outcome of MDS patients and,  
263 without implementing MRD assessment, proposed different genes associated with unfavorable  
264 prognosis.<sup>104-110</sup> Factoring in all consistent results and giving most weight to the largest study  
265 (Lindsley et al.<sup>108</sup>), which analyzed PB of 1514 MDS patients by NGS (reporting VAF threshold  
266 of 2%) before performing allogeneic HCT, we can draw the following conclusions. First, mutations  
267 in *TP53* are consistently associated with the highest risk of relapse and decreased OS<sup>28,104-</sup>  
268 <sup>107,109,110</sup> that is not influenced by conditioning intensity.<sup>108</sup> Second, mutations in RAS pathway  
269 genes are associated with shorter OS due to increased risk of relapse,<sup>107,109</sup> specifically among  
270 patients 40 years of age or older who may not have received myeloablative conditioning.<sup>108</sup>

271 Post-hoc analyses of prospective studies in MDS/AML which incorporated MRD  
272 assessment after intensive treatment and/or before HCT consistently show a higher risk of  
273 relapse for patients with MRD positivity.<sup>16,18,23,70,111</sup> By performing 10-gene NGS-MRD in 48 CR  
274 samples from a randomized trial of transplant eligible younger patients up to 65 years of age,  
275 Dillon et al. demonstrated that myeloablative conditioning mitigated the relapse risk associated  
276 with MRD positivity of non-*DTA* mutations in MDS.<sup>70</sup> Since most MDS patients are older than 70  
277 years or have other adverse factors beyond genetics, myeloablative conditioning is frequently  
278 not an option and other strategies to reduce relapse risk and improve OS must be explored. In a  
279 trial comparing reduced intensity regimens that included MDS patients (33% of 244), Craddock  
280 et al. showed that achieving a complete donor T-cell chimerism at 3 months – a potential  
281 surrogate marker for graft-versus-leukemia effect – but not the intensification of the conditioning  
282 regimen reversed the negative impact of pre-transplant MFC-MRD positivity on relapse  
283 incidence and OS.<sup>23</sup> Pretransplant MRD positivity is also not a contraindication to HCT because  
284 clinical trials like the VidazaAllo Study have demonstrated a better OS after HCT compared to  
285 continuation of HMA treatment.<sup>101</sup> In sum, these data suggest that MDS patients without MRD  
286 may avoid myeloablative conditioning and that MRD positivity is useful to steer high-risk patients  
287 into clinical trials.<sup>94,101,102</sup>

### 288 **Post-transplant Setting: Avoiding Relapse**

289 Since relapse of MDS after HCT is associated with a very poor prognosis, there is a  
290 great need for early detection and prevention through targeted intervention.<sup>112</sup> MFC, NGS, PCR  
291 and CD34+ sorted donor chimerism analyses have been successfully employed to detect MRD  
292 in the post-transplant setting (**Table 1; supplementary Table 2**). Duncavage et al. performed  
293 NGS-MRD in BM samples from 86 consecutive adult patients with MDS and secondary AML at  
294 30 and 100 days after HCT to assess mutation clearance and related risk of relapse.<sup>113</sup> Before  
295 HCT, 96% (86/90) of analyzed patients had at least one detectable somatic mutation by whole  
296 exome sequencing and 79% (68/86) with the use of a generic myeloid NGS panel of 40



297 recurrently mutated genes. At day 30 posttransplant, 30% (26/86) of patients were MRD-positive  
298 – only one patient had a sole DTA variant – defined by a VAF of  $\geq 0.5\%$  in the myeloid NGS  
299 panel. After adjustment for conditioning regimen, MRD positivity  $\geq 0.5\%$  was associated with a  
300 lower 1-year PFS compared to no detectable mutations at this threshold at 30 days  
301 posttransplant (30.8% versus 57.1%; HR for progression or death, 2.09; 95% CI, 1.18 to 3.70; P  
302 = 0.02). Importantly, patients with mutations detectable at VAF  $> 0.1\%$  at day 30 had a  
303 statistically higher risk of progression (P  $< 0.003$  by Gray's test) and a shorter progression-free  
304 survival (P = 0.021 by proportional hazards, chi-square test). However, only results of a more  
305 elaborate NGS, which also detects patient specific non-myeloid related somatic mutations, were  
306 reported for this threshold. Furthermore, MRD positivity at day 100 posttransplant which was  
307 detected in 31% (18/58) of patients by incorporating patient-specific non-myeloid related somatic  
308 mutations was also associated with a lower 1-year PFS (27.8% versus 77.5%; HR for  
309 progression or death, 2.51; 95% CI, 1.26 to 5.01; P = 0.01). In multivariable analysis, age  $> 60$   
310 years, secondary AML, *TP53* mutation and MRD positivity  $\geq 0.5\%$  at days 30 and 100 were  
311 independently associated with disease progression or death.

312 Unfortunately, there are few prospective data on the treatment of MRD of MDS after  
313 HCT, almost exclusively from AML studies that included a minority of high-risk MDS patients.  
314 <sup>103,114,115</sup> In the RELAZA2 study, Platzbecker et al. used qPCR of leukemia-specific fusion genes  
315 or mutant *NPM1* as well as donor chimerism analysis of sorted CD34+ cells from PB (threshold  
316 mixed chimerism  $< 80\%$ ) to detect MRD and initiate treatment with azacitidine. One-year relapse-  
317 free survival was 46% (95% CI, 32% to 59%) in the 53 MRD-positive patients – 5 of whom had  
318 MDS, who received the preemptive treatment. <sup>103</sup> Although efficacy of this preemptive approach  
319 is also supported by a retrospective study, <sup>116</sup> randomized controlled trials between MRD-  
320 positive and MRD-negative patients would be needed to give a definitive answer. Here, an NGS  
321 panel-based MRD assay might be more informative than MFC, as posttransplant emerging  
322 subclones with therapeutic targets could be better detected. <sup>115</sup>

## 323 **Proposition for Future MRD Analysis in MDS**

### 324 **Tailor MRD to Goals of Therapy**

325 MRD assessment, ideally a combination of NGS-MRD and MFC-MRD, should be  
326 incorporated in all clinical trials in MDS. Although CR is the ultimate goal of any MDS treatment  
327 because of the association with improved OS, we acknowledge that hematological improvement  
328 (HI) is also an important and meaningful clinical endpoint associated with improved quality of life  
329 that should be explored in clinical trials.<sup>9</sup> Genetic and morphologic responses do not perfectly  
330 correlate as shown by complete cytogenetic response (CCyR) which is associated with longer  
331 survival in high-risk MDS patients under HMA treatment but does not always lead to CR.<sup>117</sup> For  
332 that reason, in contrast to AML, we propose that the complete MRD response (MRD<sub>CR</sub>) category  
333 should always include CCyR and be distinct from morphological responses such as CR or HI.  
334 Furthermore, variants in DTA genes should be documented (DTA<sup>+/-</sup>) but generally not  
335 considered as MRD positivity (MRD<sup>+</sup>).

336 Two clinical scenarios – 1) treatment with palliative intent, 2) treatment with curative  
337 intent – should be distinguished when applying MRD response criteria. In the former scenario,  
338 the application of MRD measurement is currently only reserved for clinical trials; in the latter,  
339 MRD assessment may already be offered in individual cases. This would have two advantages.  
340 In the palliative setting, where the focus is on PFS and HI, the interaction of morphology and  
341 residual subclones would be easier to describe and to investigate (e.g. HI with MRD<sup>+</sup>-DTA<sup>+</sup>). In  
342 the curative setting, where the main goal is to predict and to prevent relapse, the morphological  
343 response might be of lesser importance after induction treatment because of HCT (e.g. marrow  
344 CR with MRD<sub>CR</sub>-DTA<sup>+</sup>). The proposed provisional MRD criteria (**Table 2**) serve as a basis for  
345 discussion and will certainly need to be adjusted by suggestions from the stakeholders'  
346 community<sup>9</sup> and results of further studies.

347 An optimal gene panel for NGS-MRD has not yet been defined for MDS. The calculation  
348 of the IPSS-M requires analysis of 31 genes for risk stratification at diagnosis.<sup>32</sup> This panel can  
349 be used as a starting point for further refinements of NGS-MRD diagnostics in MDS  
350 (**supplementary Table 3**). As a minimum, we consider the 10-gene panel, which has been  
351 described as prognostic in patients with MDS and AML before conditioning for HCT  
352 (**supplementary Table 4**).<sup>70</sup> All detected mutations should be considered potential MRD  
353 markers (**supplementary Table 1**).

### 354 **Timepoints of MRD Assessment**

355 The optimal MRD measurement timepoints are not known and will always reflect the  
356 design of published clinical trials that demonstrate outcome differences between MRD-positive  
357 and MRD-negative patients. No evidence-based recommendation can be given for the setting of  
358 palliative treatment. Outside of clinical trials, a pragmatic suggestion would be to perform MRD  
359 testing in patients who have a long-lasting remission with HMAs and wish to reduce therapy, or  
360 who have indeterminate cytopenia despite achieving CCyR. For patients treated with the  
361 intention of cure, we pragmatically suggest performing MRD testing in BM for remission  
362 assessment before HCT as well as on days +30 and +100 after HCT. These timepoints would  
363 allow conditioning regimen (myeloablative versus reduced intensity) and immunosuppression  
364 (faster vs normal tapering of immunosuppressive agents) to be adjusted as well as optional  
365 donor lymphocyte infusion to be planned. If a molecular marker is present, further NGS-MRD  
366 assessments could be performed every 4-8 weeks in PB. Any MRD<sup>+</sup> results should be confirmed  
367 by further testing to estimate clone kinetics.

### 368 **Potential Role of New Methodologies**

369 A major drawback of NGS-MRD is that the reported VAF represents the average  
370 frequency within a bulk cell population, making it impossible to provide information on the co-  
371 occurrence of multiple variants within a single subclone of that cell population.<sup>79</sup> Especially in

372 MDS, where CH is an integral part of its pathogenesis, the inability to distinguish residual CH  
373 from LSCs is still an obstacle to clearly establishing the presence of MRD in some cases. Single-  
374 cell analysis has great potential to revolutionize MRD assessment in this regard because it is  
375 able to resolve clonal architecture. For example, sequencing of single cells from enriched LSCs  
376 at diagnosis and during remission could explain which combinations of mutations are found in  
377 the same cell and steer more sensitive NGS-MRD detection. Recently, Dillon et al. have shown  
378 in a proof-of-principle in three AML patients that a tailored single-cell analysis integrating patient-  
379 specific mutations and structural variants from whole-genome sequencing as well as cell surface  
380 markers is able to determine which genetic alterations exactly are present in a single cell.<sup>80</sup>  
381 Single cell MRD analysis is in the early stages of development. Further studies, ideally in the  
382 context of prospective clinical trials, are necessary to demonstrate feasibility on a large scale.

383 Another promising approach to detect MRD is to perform NGS in CD34+ (or alternatively  
384 CD117+) selected cells from PB after magnetic cell separation or flow cytometric sorting.<sup>75</sup> In an  
385 analysis of 40 MDS/AML patients in CR after HCT, Stasik et al. demonstrated an impressively  
386 high sensitivity of 100% and specificity of 91% for detecting molecular relapse.<sup>75</sup> The lower limit  
387 of MRD detection was  $10^{-6}$ , about 10-fold more sensitive than the measurement of donor  
388 chimerism as performed in the RELAZA2 study, and PB was superior to BM as a source of  
389 CD34+ cells.

390 Regarding minimally invasive MRD assessment, serial analysis of circulating cell-free  
391 tumor DNA for leukemia-specific mutations in serum may be the optimal approach for cytopenic  
392 MDS/AML patients. Previous studies in the post-HCT setting in patients with MDS/AML have  
393 demonstrated the principal feasibility of this methodology that must be standardized and  
394 prospectively investigated in different clinical scenarios.<sup>47,48</sup>

### 395 **Standardization Efforts**

396           The standardization of MRD methods is the key to accomplish reproducibility and  
397 comparability. The MRD working group of the ELN has published a blueprint on how to  
398 successfully carry out such an endeavor in AML. Reproducibility has to be demonstrated in  
399 clinical trials using a published standardized methodology. This means that, in addition to  
400 technological advancement, considerable standardization efforts will also be necessary in MDS  
401 in the future. A first step should be the definition of uniform MRD criteria.

### 402 **Open Questions**

403           Because the extent of discordance between MRD measured by MFC and NGS is  
404 currently unknown in MDS, we recommend that both methods be prospectively studied in  
405 parallel to determine clinically meaningful detection thresholds. Additionally, when NGS-MRD  
406 testing is used at specific timepoints in clinical trials, comparison of BM and PB source materials  
407 is recommended. The potential role of LSC based detection of MRD is unknown for MDS and  
408 should be explored. If patients are randomized between intensive versus non-intensive therapy,  
409 MRD assessment should be used to answer the question whether MRD negativity has the same  
410 value after both treatment types and what specific mutations are affected by either strategy.  
411 Copy number abnormalities and allelic imbalances including copy-neutral loss of heterozygosity  
412 are important in the pathogenesis of MDS but have rarely been discussed in the context of MRD.  
413 Furthermore, the significance of uncommon mutations from agnostic NGS approaches should be  
414 explored in more granularity to answer the question whether all non-DTA mutations or  
415 combinations thereof are predictive for relapse or progression. Single-cell sequencing is  
416 providing increasing insight into the role of subclones in treatment resistance and relapse. This  
417 technology could be used to determine the stage – diagnosis or relapse – at which escape  
418 clones emerge and thus possibly predict their occurrence.

## 419 **Summary**

420           A negative MRD test result indicates that there is no evidence of disease present, above  
421 a predefined test threshold. However, although MRD measurements give an important  
422 prognostic estimate, this estimate is not absolute because relapse is also observed in MRD-  
423 negative patients and MRD assessment is potentially hampered by source material processing,  
424 technique used, benign CH and timepoint of investigation. The landscape of MRD in MDS  
425 continues to evolve, with the introduction of new methods such as single-cell sequencing,  
426 however, a formal working MRD definition is needed now. We propose MRD response criteria  
427 built on currently available evidence. Since there remains no curative therapy for most MDS  
428 patients, implementation of MRD testing is an important part of clinical trial design and should be  
429 a secondary endpoint to achieve inter-trial comparability and efficacy quantification, and to  
430 improve our understanding of the relationship between residual CH and relapse. Clinically useful  
431 evidence to establish MRD as a biomarker will require both high quality randomized controlled  
432 trials and large collaborations.

## 433 **Acknowledgments**

434           This work was supported by funding from the Intramural Research Program, National  
435 Institutes of Health, National Cancer Institute, Center for Cancer Research.

## 436 **Author contributions**

437           Conception of the work: E.S., S.Z.P; Interpretation of Data: E.S., S.F., P.D.A., S.Z.P;  
438 Drafted the manuscript: E.S., S.F., P.D.A., S.Z.P. All authors have seen and approved the  
439 manuscript being submitted.

## 440 **Conflict of interest**

441           E.S.: Amgen (Honoraria).

442           P.D.A.: No conflict of interest.

443 S.F.: No conflict of interest

444 S.Z.P.: No conflict of interest.

## 445 **Disclaimer**

446 The views expressed in this work do not represent the official views of the National  
447 Institutes of Health or the United States Government.

## 448 **References**

- 449 1. Short NJ, Zhou S, Fu C, et al. Association of Measurable Residual Disease With Survival  
450 Outcomes in Patients With Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.  
451 *JAMA Oncol.* 2020;6(12):1890-1899.
- 452 2. Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease With Clinical  
453 Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. *JAMA Oncol.*  
454 2017;3(7):e170580.
- 455 3. Heuser M, Freeman SD, Ossenkoppele GJ, et al. 2021 Update on MRD in acute myeloid  
456 leukemia: a consensus document from the European LeukemiaNet MRD Working Party. *Blood.*  
457 2021;138(26):2753-2767.
- 458 4. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization  
459 Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.  
460 *Leukemia.* 2022;36(7):1703-1719.
- 461 5. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of  
462 Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data.  
463 *Blood.* 2022;140(11):1200-1228.
- 464 6. Estey E, Hasserjian RP, Dohner H. Distinguishing AML from MDS: a fixed blast  
465 percentage may no longer be optimal. *Blood.* 2022;139(3):323-332.
- 466 7. Cazzola M. Myelodysplastic Syndromes. *N Engl J Med.* 2020;383(14):1358-1374.
- 467 8. Kim N, Pavletic S, Norsworthy KJ. Meaningful response criteria for myelodysplastic  
468 syndromes. *Br J Haematol.* 2022;196(5):1137-1148.
- 469 9. Zeidan AM, Platzbecker U, Bewersdorf JP, et al. Consensus proposal for revised  
470 International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.  
471 *Blood.* 2023;141(17):2047-2061.
- 472 10. Tettero JM, Freeman S, Buecklein V, et al. Technical Aspects of Flow Cytometry-based  
473 Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the  
474 European LeukemiaNet MRD Working Party. *Hemasphere.* 2022;6(1):e676.
- 475 11. Li SQ, Xu LP, Wang Y, et al. An LSC-based MRD assay to complement the traditional  
476 MFC method for prediction of AML relapse: a prospective study. *Blood.* 2022;140(5):516-520.
- 477 12. Porwit A, Bene MC, Duetz C, et al. Multiparameter flow cytometry in the evaluation of  
478 myelodysplasia: Analytical issues: Recommendations from the European  
479 LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group.  
480 *Cytometry B Clin Cytom.* 2023;104(1):27-50.
- 481 13. Kern W, Westers TM, Bellos F, et al. Multicenter prospective evaluation of diagnostic  
482 potential of flow cytometric aberrancies in myelodysplastic syndromes by the ELN iMDS flow  
483 working group. *Cytometry B Clin Cytom.* 2023;104(1):51-65.

- 484 14. Simoes C, Chillon MC, Martinez-Cuadron D, et al. Integrated flow cytometry and  
485 sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia. *Blood*  
486 *Adv.* 2023;7(1):167-173.
- 487 15. van Spronsen MF, Hanekamp D, Westers TM, et al. Immunophenotypic aberrant  
488 hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression.  
489 *Leukemia.* 2023;37(3):680-690.
- 490 16. Freeman SD, Virgo P, Couzens S, et al. Prognostic relevance of treatment response  
491 measured by flow cytometric residual disease detection in older patients with acute myeloid  
492 leukemia. *J Clin Oncol.* 2013;31(32):4123-4131.
- 493 17. Wedge E, Hansen JW, Dybedal I, et al. Allogeneic Hematopoietic Stem Cell  
494 Transplantation for Chronic Myelomonocytic Leukemia: Clinical and Molecular Genetic  
495 Prognostic Factors in a Nordic Population. *Transplant Cell Ther.* 2021;27(12):991 e991-991  
496 e999.
- 497 18. Janssen J, Lowenberg B, Manz M, et al. Addition of the nuclear export inhibitor selinexor  
498 to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk  
499 myelodysplastic syndrome. *Leukemia.* 2022;36(9):2189-2195.
- 500 19. Boddu P, Jorgensen J, Kantarjian H, et al. Achievement of a negative minimal residual  
501 disease state after hypomethylating agent therapy in older patients with AML reduces the risk of  
502 relapse. *Leukemia.* 2018;32(1):241-244.
- 503 20. Maiti A, DiNardo CD, Wang SA, et al. Prognostic value of measurable residual disease  
504 after venetoclax and decitabine in acute myeloid leukemia. *Blood Adv.* 2021;5(7):1876-1883.
- 505 21. Pratz KW, Jonas BA, Pullarkat V, et al. Measurable Residual Disease Response and  
506 Prognosis in Treatment-Naive Acute Myeloid Leukemia With Venetoclax and Azacitidine. *J Clin*  
507 *Oncol.* 2022;40(8):855-865.
- 508 22. Simoes C, Paiva B, Martinez-Cuadron D, et al. Measurable residual disease in elderly  
509 acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial. *Blood Adv.*  
510 2021;5(3):760-770.
- 511 23. Craddock C, Jackson A, Loke J, et al. Augmented Reduced-Intensity Regimen Does Not  
512 Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. *J Clin Oncol.*  
513 2021;39(7):768-778.
- 514 24. Paras G, Morsink LM, Othus M, et al. Conditioning intensity and peritransplant flow  
515 cytometric MRD dynamics in adult AML. *Blood.* 2022;139(11):1694-1706.
- 516 25. Bernal T, Diez-Campelo M, Godoy V, et al. Role of minimal residual disease and  
517 chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid  
518 leukemia and high-risk myelodysplastic syndrome. *Leuk Res.* 2014;38(5):551-556.
- 519 26. Festuccia M, Deeg HJ, Gooley TA, et al. Minimal Identifiable Disease and the Role of  
520 Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and  
521 Acute Myelogenous Leukemia Evolving from Myelodysplastic Syndrome. *Biol Blood Marrow*  
522 *Transplant.* 2016;22(7):1227-1233.
- 523 27. Mo XD, Qin YZ, Zhang XH, et al. Minimal residual disease monitoring and preemptive  
524 immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell  
525 transplantation. *Ann Hematol.* 2016;95(8):1233-1240.
- 526 28. Hou C, Zhou L, Yang M, et al. The Prognostic Value of Early Detection of Minimal  
527 Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for  
528 Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell  
529 Transplantation. *Front Oncol.* 2021;11:700234.
- 530 29. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of  
531 driver mutations in myelodysplastic syndromes. *Blood.* 2013;122(22):3616-3627; quiz 3699.
- 532 30. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients  
533 with myelodysplastic syndromes. *Leukemia.* 2014;28(2):241-247.
- 534 31. Ogawa S. Genetics of MDS. *Blood.* 2019;133(10):1049-1059.



- 535 32. Bernard E, Tuechler H, Greenberg PL, et al. Molecular International Prognostic Scoring  
536 System for Myelodysplastic Syndromes. *NEJM Evidence*. 2022;1(7):EVID0a2200008.
- 537 33. Schwartz JR, Ma J, Lamprecht T, et al. The genomic landscape of pediatric  
538 myelodysplastic syndromes. *Nat Commun*. 2017;8(1):1557.
- 539 34. Bhai P, Hsia CC, Schenkel LC, et al. Clinical Utility of Implementing a Frontline NGS-  
540 Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies. *Mol*  
541 *Diagn Ther*. 2022;26(3):333-343.
- 542 35. Kennedy SR, Schmitt MW, Fox EJ, et al. Detecting ultralow-frequency mutations by  
543 Duplex Sequencing. *Nat Protoc*. 2014;9(11):2586-2606.
- 544 36. Young AL, Wong TN, Hughes AE, et al. Quantifying ultra-rare pre-leukemic clones via  
545 targeted error-corrected sequencing. *Leukemia*. 2015;29(7):1608-1611.
- 546 37. Gui G, Hourigan CS. Measurable Residual Disease Assessment as a Surrogate Marker  
547 in New Drug Development in Acute Myeloid Leukemia. *Cancer J*. 2022;28(1):73-77.
- 548 38. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer  
549 risk inferred from blood DNA sequence. *N Engl J Med*. 2014;371(26):2477-2487.
- 550 39. Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes  
551 dynamically adapt and evolve upon therapy response and failure. *Blood*. 2016;128(9):1246-  
552 1259.
- 553 40. Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in  
554 myelodysplastic syndromes. *Nat Genet*. 2017;49(2):204-212.
- 555 41. Thol F, Gabdoulline R, Liebich A, et al. Measurable residual disease monitoring by NGS  
556 before allogeneic hematopoietic cell transplantation in AML. *Blood*. 2018;132(16):1703-1713.
- 557 42. Balagopal V, Hantel A, Kadri S, et al. Measurable residual disease monitoring for  
558 patients with acute myeloid leukemia following hematopoietic cell transplantation using error  
559 corrected hybrid capture next generation sequencing. *PLoS One*. 2019;14(10):e0224097.
- 560 43. Falconi G, Fabiani E, Piciocchi A, et al. Somatic mutations as markers of outcome after  
561 azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes.  
562 *Leukemia*. 2019;33(3):785-790.
- 563 44. Godwin CD, Zhou Y, Othus M, et al. Acute myeloid leukemia measurable residual  
564 disease detection by flow cytometry in peripheral blood vs bone marrow. *Blood*.  
565 2021;137(4):569-572.
- 566 45. Skou AS, Juul-Dam KL, Ommen HB, Hasle H. Peripheral blood molecular measurable  
567 residual disease is sufficient to identify patients with acute myeloid leukaemia with imminent  
568 clinical relapse. *Br J Haematol*. 2021;195(3):310-327.
- 569 46. Duncavage EJ, Uy GL, Petti AA, et al. Mutational landscape and response are conserved  
570 in peripheral blood of AML and MDS patients during decitabine therapy. *Blood*.  
571 2017;129(10):1397-1401.
- 572 47. Nakamura S, Yokoyama K, Shimizu E, et al. Prognostic impact of circulating tumor DNA  
573 status post-allogeneic hematopoietic stem cell transplantation in AML and MDS. *Blood*.  
574 2019;133(25):2682-2695.
- 575 48. Pasca S, Guo M, Wang SY, et al. Cell-Free DNA (cfDNA)-Based Measurable Residual  
576 Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow  
577 Transplant (alloBMT) in Patients with Myeloid Malignancies. *Blood*. 2022;140(Supplement  
578 1):3429-3430.
- 579 49. Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults:  
580 2022 recommendations from an international expert panel on behalf of the ELN. *Blood*.  
581 2022;140(12):1345-1377.
- 582 50. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated  
583 with adverse outcomes. *N Engl J Med*. 2014;371(26):2488-2498.
- 584 51. Acuna-Hidalgo R, Sengul H, Steehouwer M, et al. Ultra-sensitive Sequencing Identifies  
585 High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. *Am J*  
586 *Hum Genet*. 2017;101(1):50-64.

- 587 52. Midic D, Rinke J, Perner F, et al. Prevalence and dynamics of clonal hematopoiesis  
588 caused by leukemia-associated mutations in elderly individuals without hematologic disorders.  
589 *Leukemia*. 2020;34(8):2198-2205.
- 590 53. Hecker JS, Hartmann L, Riviere J, et al. CHIP and hips: clonal hematopoiesis is common  
591 in patients undergoing hip arthroplasty and is associated with autoimmune disease. *Blood*.  
592 2021;138(18):1727-1732.
- 593 54. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential  
594 and its distinction from myelodysplastic syndromes. *Blood*. 2015;126(1):9-16.
- 595 55. Greenberg PL, Tuechler H, Schanz J, et al. Cytopenia levels for aiding establishment of  
596 the diagnosis of myelodysplastic syndromes. *Blood*. 2016;128(16):2096-2097.
- 597 56. Stauber J, Grealley JM, Steidl U. Preleukemic and leukemic evolution at the stem cell  
598 level. *Blood*. 2021;137(8):1013-1018.
- 599 57. Menssen AJ, Khanna A, Miller CA, et al. Convergent Clonal Evolution of Signaling Gene  
600 Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. *Blood Cancer Discov*.  
601 2022;3(4):330-345.
- 602 58. Guess T, Potts CR, Bhat P, et al. Distinct Patterns of Clonal Evolution Drive  
603 Myelodysplastic Syndrome Progression to Secondary Acute Myeloid Leukemia. *Blood Cancer*  
604 *Discov*. 2022;3(4):316-329.
- 605 59. Niroula A, Sekar A, Murakami MA, et al. Distinction of lymphoid and myeloid clonal  
606 hematopoiesis. *Nat Med*. 2021;27(11):1921-1927.
- 607 60. Saiki R, Momozawa Y, Nannya Y, et al. Combined landscape of single-nucleotide  
608 variants and copy number alterations in clonal hematopoiesis. *Nat Med*. 2021;27(7):1239-1249.
- 609 61. Tsaknakis G, Galli A, Papadakis S, et al. Incidence and prognosis of clonal  
610 hematopoiesis in patients with chronic idiopathic neutropenia. *Blood*. 2021;138(14):1249-1257.
- 611 62. Galli A, Todisco G, Catamo E, et al. Relationship between clone metrics and clinical  
612 outcome in clonal cytopenia. *Blood*. 2021;138(11):965-976.
- 613 63. Malcovati L, Galli A, Travaglini E, et al. Clinical significance of somatic mutation in  
614 unexplained blood cytopenia. *Blood*. 2017;129(25):3371-3378.
- 615 64. Takahashi K, Wang F, Kantarjian H, et al. Preleukaemic clonal haemopoiesis and risk of  
616 therapy-related myeloid neoplasms: a case-control study. *Lancet Oncol*. 2017;18(1):100-111.
- 617 65. Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal Hematopoiesis Associated With  
618 Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. *J Clin Oncol*.  
619 2017;35(14):1598-1605.
- 620 66. Soerensen JF, Aggerholm A, Rosenberg CA, et al. Clonal evolution in patients  
621 developing therapy-related myeloid neoplasms following autologous stem cell transplantation.  
622 *Bone Marrow Transplant*. 2022;57(3):460-465.
- 623 67. Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of  
624 TP53-mutated therapy-related myeloid neoplasms. *Blood*. 2022;140(16):1753-1763.
- 625 68. Schulz E, Kashofer K, Heitzer E, et al. Preexisting TP53 mutation in therapy-related  
626 acute myeloid leukemia. *Ann Hematol*. 2015;94(3):527-529.
- 627 69. Hsu JI, Dayaram T, Tovy A, et al. PPM1D Mutations Drive Clonal Hematopoiesis in  
628 Response to Cytotoxic Chemotherapy. *Cell Stem Cell*. 2018;23(5):700-713 e706.
- 629 70. Dillon LW, Gui G, Logan BR, et al. Impact of Conditioning Intensity and Genomics on  
630 Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome. *JCO*  
631 *Precis Oncol*. 2021;5.
- 632 71. Heuser M, Heida B, Buttner K, et al. Posttransplantation MRD monitoring in patients with  
633 AML by next-generation sequencing using DTA and non-DTA mutations. *Blood Adv*.  
634 2021;5(9):2294-2304.
- 635 72. Hourigan CS, Dillon LW, Gui G, et al. Impact of Conditioning Intensity of Allogeneic  
636 Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. *J Clin*  
637 *Oncol*. 2020;38(12):1273-1283.

- 638 73. Morita K, Kantarjian HM, Wang F, et al. Clearance of Somatic Mutations at Remission  
639 and the Risk of Relapse in Acute Myeloid Leukemia. *J Clin Oncol*. 2018;36(18):1788-1797.
- 640 74. Hasserjian RP, Steensma DP, Graubert TA, Ebert BL. Clonal hematopoiesis and  
641 measurable residual disease assessment in acute myeloid leukemia. *Blood*. 2020;135(20):1729-  
642 1738.
- 643 75. Stasik S, Burkhard-Meier C, Kramer M, et al. Deep sequencing in CD34+ cells from  
644 peripheral blood enables sensitive detection of measurable residual disease in AML. *Blood Adv*.  
645 2022;6(11):3294-3303.
- 646 76. Frick M, Chan W, Arends CM, et al. Role of Donor Clonal Hematopoiesis in Allogeneic  
647 Hematopoietic Stem-Cell Transplantation. *J Clin Oncol*. 2019;37(5):375-385.
- 648 77. Gibson CJ, Kim HT, Zhao L, et al. Donor Clonal Hematopoiesis and Recipient Outcomes  
649 After Transplantation. *J Clin Oncol*. 2022;40(2):189-201.
- 650 78. Brambati C, Galbiati S, Xue E, et al. Droplet digital polymerase chain reaction for  
651 DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse  
652 after allogeneic hematopoietic stem cell transplantation. *Haematologica*. 2016;101(4):e157-161.
- 653 79. Miles LA, Bowman RL, Merlinsky TR, et al. Single-cell mutation analysis of clonal  
654 evolution in myeloid malignancies. *Nature*. 2020;587(7834):477-482.
- 655 80. Dillon LW, Ghannam J, Nosiri C, et al. Personalized Single-Cell Proteogenomics to  
656 Distinguish Acute Myeloid Leukemia from Non-Malignant Clonal Hematopoiesis. *Blood Cancer*  
657 *Discov*. 2021;2(4):319-325.
- 658 81. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to  
659 standardize response criteria for myelodysplastic syndromes. *Blood*. 2000;96(12):3671-3674.
- 660 82. Steensma DP, Fenaux P, Van Eygen K, et al. Imetelstat Achieves Meaningful and  
661 Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk  
662 Myelodysplastic Syndromes in a Phase II Study. *J Clin Oncol*. 2021;39(1):48-56.
- 663 83. Yun S, Geyer SM, Komrokji RS, et al. Prognostic significance of serial molecular  
664 annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML).  
665 *Leukemia*. 2021;35(4):1145-1155.
- 666 84. Nannya Y, Tobiasson M, Sato S, et al. Post-azacitidine clone size predicts outcome of  
667 patients with myelodysplastic syndromes and related myeloid neoplasms. *Blood Adv*. 2023.
- 668 85. Food and Drug Administration. Hematologic Malignancies: Regulatory Considerations for  
669 Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment  
670 Guidance for Industry. Rockville, MD; 2018.
- 671 86. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del(5q)  
672 myelodysplasia in remission. *N Engl J Med*. 2010;363(11):1025-1037.
- 673 87. Sekeres MA, Swern AS, Giagounidis A, et al. The impact of lenalidomide exposure on  
674 response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q).  
675 *Blood Cancer J*. 2018;8(10):90.
- 676 88. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic  
677 syndromes with del(5q) predict disease progression. *J Clin Oncol*. 2011;29(15):1971-1979.
- 678 89. Mossner M, Jann JC, Nowak D, et al. Prevalence, clonal dynamics and clinical impact of  
679 TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated  
680 with lenalidomide: results from a prospective multicenter study of the german MDS study group  
681 (GMDS). *Leukemia*. 2016;30(9):1956-1959.
- 682 90. Lode L, Menard A, Flet L, et al. Emergence and evolution of TP53 mutations are key  
683 features of disease progression in myelodysplastic patients with lower-risk del(5q) treated with  
684 lenalidomide. *Haematologica*. 2018;103(4):e143-e146.
- 685 91. Fenaux P, Haase D, Santini V, et al. Myelodysplastic syndromes: ESMO Clinical Practice  
686 Guidelines for diagnosis, treatment and follow-up(dagger☆). *Ann Oncol*. 2021;32(2):142-156.
- 687 92. Uy GL, Duncavage EJ, Chang GS, et al. Dynamic changes in the clonal structure of MDS  
688 and AML in response to epigenetic therapy. *Leukemia*. 2017;31(4):872-881.

- 689 93. Nazha A, Sekeres MA, Bejar R, et al. Genomic Biomarkers to Predict Resistance to  
690 Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial  
691 Intelligence. *JCO Precis Oncol.* 2019;3.
- 692 94. Hunter AM, Komrokji RS, Yun S, et al. Baseline and serial molecular profiling predicts  
693 outcomes with hypomethylating agents in myelodysplastic syndromes. *Blood Adv.*  
694 2021;5(4):1017-1028.
- 695 95. Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, et al. Genomic context and  
696 TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.  
697 *Blood Adv.* 2020;4(3):482-495.
- 698 96. Sallman DA, DeZern AE, Garcia-Manero G, et al. Eprenetapopt (APR-246) and  
699 Azacitidine in TP53-Mutant Myelodysplastic Syndromes. *J Clin Oncol.* 2021;39(14):1584-1594.
- 700 97. Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia  
701 and Myelodysplastic Syndromes. *N Engl J Med.* 2016;375(21):2023-2036.
- 702 98. Short NJ, Kantarjian HM, Loghavi S, et al. Treatment with a 5-day versus a 10-day  
703 schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a  
704 randomised phase 2 trial. *Lancet Haematol.* 2019;6(1):e29-e37.
- 705 99. Sallman DA, Al Malki MM, Asch AS, et al. Magrolimab in Combination With Azacitidine in  
706 Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study. *J Clin*  
707 *Oncol.* 2023;JCO2201794.
- 708 100. Ferraro F, Gruszczynska A, Ruzinova MB, et al. Decitabine salvage for TP53-mutated,  
709 relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. *Haematologica.*  
710 2022;107(7):1709-1713.
- 711 101. Kroger N, Sockel K, Wolschke C, et al. Comparison Between 5-Azacitidine Treatment  
712 and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to  
713 Donor Availability (VidazaAllo Study). *J Clin Oncol.* 2021;39(30):3318-3327.
- 714 102. Nakamura R, Saber W, Martens MJ, et al. Biologic Assignment Trial of Reduced-  
715 Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years  
716 of Age With Advanced Myelodysplastic Syndrome. *J Clin Oncol.* 2021;39(30):3328-3339.
- 717 103. Platzbecker U, Middeke JM, Sockel K, et al. Measurable residual disease-guided  
718 treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic  
719 syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.  
720 *Lancet Oncol.* 2018;19(12):1668-1679.
- 721 104. Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in  
722 patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. *J Clin*  
723 *Oncol.* 2014;32(25):2691-2698.
- 724 105. Della Porta MG, Galli A, Bacigalupo A, et al. Clinical Effects of Driver Somatic Mutations  
725 on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic  
726 Hematopoietic Stem-Cell Transplantation. *J Clin Oncol.* 2016;34(30):3627-3637.
- 727 106. Hamilton BK, Visconte V, Jia X, et al. Impact of allogeneic hematopoietic cell transplant  
728 in patients with myeloid neoplasms carrying spliceosomal mutations. *Am J Hematol.*  
729 2016;91(4):406-409.
- 730 107. Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and  
731 secondary acute myeloid leukemia: impact on outcome of stem cell transplantation. *Blood.*  
732 2017;129(17):2347-2358.
- 733 108. Lindsley RC, Saber W, Mar BG, et al. Prognostic Mutations in Myelodysplastic Syndrome  
734 after Stem-Cell Transplantation. *N Engl J Med.* 2017;376(6):536-547.
- 735 109. Heuser M, Gabdoulline R, Loffeld P, et al. Individual outcome prediction for  
736 myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after  
737 allogeneic hematopoietic cell transplantation. *Ann Hematol.* 2017;96(8):1361-1372.
- 738 110. Kharfan-Dabaja MA, Komrokji RS, Zhang Q, et al. TP53 and IDH2 Somatic Mutations  
739 Are Associated With Inferior Overall Survival After Allogeneic Hematopoietic Cell

- 740 Transplantation for Myelodysplastic Syndrome. *Clin Lymphoma Myeloma Leuk.*  
741 2017;17(11):753-758.
- 742 111. Craddock C, Jackson A, Freeman SD. Reply to G. Gui et al. *J Clin Oncol.*  
743 2021;39(21):2416-2417.
- 744 112. Schmid C, de Wreede LC, van Biezen A, et al. Outcome after relapse of myelodysplastic  
745 syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation:  
746 a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of  
747 the European Society of Blood and Marrow Transplantation. *Haematologica.* 2018;103(2):237-  
748 245.
- 749 113. Duncavage EJ, Jacoby MA, Chang GS, et al. Mutation Clearance after Transplantation  
750 for Myelodysplastic Syndrome. *N Engl J Med.* 2018;379(11):1028-1041.
- 751 114. Schroeder T, Czibere A, Platzbecker U, et al. Azacitidine and donor lymphocyte infusions  
752 as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.  
753 *Leukemia.* 2013;27(6):1229-1235.
- 754 115. Woo J, Howard NP, Storer BE, et al. Mutational analysis in serial marrow samples during  
755 azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or  
756 myelodysplastic syndromes. *Haematologica.* 2017;102(6):e216-e218.
- 757 116. Guillaume T, Thepot S, Peterlin P, et al. Prophylactic or Preemptive Low-Dose  
758 Azacitidine and Donor Lymphocyte Infusion to Prevent Disease Relapse following Allogeneic  
759 Transplantation in Patients with High-Risk Acute Myelogenous Leukemia or Myelodysplastic  
760 Syndrome. *Transplant Cell Ther.* 2021;27(10):839 e831-839 e836.
- 761 117. Jabbour E, Strati P, Cabrero M, et al. Impact of achievement of complete cytogenetic  
762 response on outcome in patients with myelodysplastic syndromes treated with hypomethylating  
763 agents. *Am J Hematol.* 2017;92(4):351-358.
- 764 118. Ma YY, Wei ZL, Xu YJ, et al. Poor pretransplantation minimal residual disease clearance  
765 as an independent prognostic risk factor for survival in myelodysplastic syndrome with excess  
766 blasts: A multicenter, retrospective cohort study. *Cancer.* 2023.

767 **Figure and Table Legends.**

768 **Figure 1.** Measurable Residual Disease Monitoring of MDS by Flow Cytometry: Potential  
769 Approaches.

770 **Figure 2.** Schematic depiction of the polyclonal evolution and trackable somatic mutations from  
771 clonal hematopoiesis, through CHIP and CCUS to MDS/AML. Each colored dot within the cell  
772 represents a distinct mutation, with two different transformed clones (dark circles) developing  
773 over time and one outcompeting the other (so called clone sweeping<sup>40</sup>). NGS of the bulk  
774 population can only detect genetic alterations with a frequency above the detection limit (LOD)  
775 which depends on the error-corrected sequencing methodology used. The variant allele  
776 frequency (VAF) represents the variant frequency within the bulk population without information  
777 on the co-occurrence of variants within a single subclone of that population that is under  
778 constant intrinsic competition and extrinsic pressure (treatment). Depending on the bulk  
779 composition, the same VAF can represent different mutational states on a single-cell level  
780 (demonstrated by chromosomes in the right lower corner of the figure) such as biallelic versus  
781 monoallelic mutation, homozygous versus hemizygous or heterozygous mutations. Importantly,  
782 such allelic imbalances, e.g. biallelic *TP53* mutation, are not limited to MDS/AML but can also be  
783 found in CH, CHIP and CCUS. CR, complete remission; CTx, chemotherapy; HMA,  
784 hypomethylating agent; LOD, limit of detection. The figure was adapted and modified from  
785 Stauber et al.<sup>56</sup>

786 **Table 1.** Summary of important studies with MDS patients and reported MRD results including  
787 allogeneic HCT. A more extensive version of this table can be found in the supplementary data  
788 (**supplementary Table 2**).

789 **Table 2.** Proposition for MRD response criteria in MDS.

790 Table 1.

Study	Population	Study design	Intervention	MRD methodology	Results
<b>Mixed populations including palliative therapy</b>					
<b>Welch et al., 2016<sup>97</sup></b>	MDS (N=26), AML (de novo, N=54; relapsed, N=36)	Prospective, uncontrolled trial (N=84) and extension cohort (N=32)	10-day or 5-day decitabine	WES, NGS gene panel (LOD not specified)	Rate of any mutation clearance associated with morphological response
<b>Hunter et al., 2021<sup>94</sup></b>	MDS (N=210), MDS/MPN (N=16), AML (N=102), t-MN (N=60)	Retrospective	HMA therapy (7% additional agents)	NGS gene panel (VAF ≥5%)	<i>TP53</i> mutation clearance associated with longer median survival (15.6 [negative] versus 7.7 [positive] months; P=0.001)
<b>Sallman et al., 2021<sup>96</sup></b>	MDS (N=40), AML (N=11), MDS/MPN (N=4)	Phase 1b/2	Eprenetapopt plus azacitidine	NGS (PB; LOD 0.1%)	<i>TP53</i> mutation clearance associated with CR
<b>Steensma et al., 2021<sup>82</sup></b>	ESA relapsed/refractory lower-risk MDS (N=57)	Phase 2	Imetelstat	NGS (BM, PB)	<i>SF3B1</i> VAF reduction correlated with duration of transfusion independence
<b>Yun et al., 2021<sup>83</sup></b>	MDS (N=95), secondary AML (N=52), MDS/MPN (N=10)	Retrospective	HMA (74%), intensive chemotherapy (45%), HCT (24%)	NGS gene-panel (BM, PB; MRD VAF ≥5%)	MRD negativity (median OS not reached versus 18.5 months; P=0.002) and <i>TP53</i> mutation clearance <5% were associated with better OS
<b>Sallman et al., 2023<sup>99</sup></b>	MDS (N=95)	Phase 1b	Magrolimab plus azacitidine	MFC (LOD 0.02%)	- Small, heterogeneous high-risk cohort with 26% <i>TP53</i> mutant MDS - CR rate 33%, MRD negativity rate 23% - Trend for improved OS in patients who became MRD-negative
<b>Nannya et al. 2023<sup>84</sup></b>	MDS (N=384)	Retrospective	Azacitidine	NGS gene panel (≥1%; LOD not specified)	Except for <i>DDX41</i> , post-treatment (≥ 4 cycles) clone size correlated with response

Pretransplant					
<b>Festuccia et al., 2016</b> <sup>26</sup>	MDS (N=285; 23% had advanced to AML before HCT) CMML (N=4)	Retrospective	HCT	MFC-MRD (LOD 0.001%-0.1%) plus cytogenetics/FISH	MRD status associated with CIR
<b>Dillon et al., 2020</b> <sup>70</sup>	MDS (N=48)	Subgroup analysis of a prospective phase 3 trial	RIC (N=23) versus MAC (N=25)	NGS 10-gene panel (PB)	- MRD status associated with OS (55% versus 79%; P=0.045) and CIR (40% versus 11%; P=0.022) at 3 years - Higher relapse rate in MRD-positive patients randomly assigned to RIC versus MAC: 60% versus 8% (P=0.010)
<b>Craddock et al., 2021</b> <sup>23,111</sup>	AML (N=164), MDS (N=80)	Phase 2 randomized trial	Standard RIC (N=108) versus intensified FLAMSA-Bu RIC (N=108)	MFC (BM; LOD 0.02%-0.05%)	Pretransplant MRD positivity associated with 2-year CIR in MDS: 50.0% versus 21.1% (P=0.020)
<b>Ma et al., 2023</b> <sup>118</sup>	MDS-EB (N=103)	Retrospective	HCT	MFC (BM; LOD <0.01%-0.05%)	MRD status associated with DFS and OS
Posttransplant					
<b>Bernal et al., 2014</b> <sup>25</sup>	AML (N=49), MDS (N=38)	Retrospective	MAC (16%), RIC (84%)	MFC (BM; >0.01%)	- Positive pre-transplant MRD associated with positive MRD at day +100 - Positive MRD at day +100 associated with relapse (OR 6.55)
<b>Duncavage et al., 2018</b> <sup>113</sup>	MDS (N=90)	Retrospective	RIC (42%), MAC (58%)	NGS (BM; VAF ≥0.5%)	- 37% of patients were MRD positive at day +30, 31% at day +100 - MRD-positivity at days +30 and +100 associated with higher risk of disease progression or death



<b>Nakamura et al. 2019<sup>47</sup></b>	AML (N=37), MDS (N=14)	Retrospective	HCT (MAC 100%; 92% cord blood)	Personalized droplet digital PCR assay (circulating tumor DNA from serum or DNA from matched BM; median LOD 0.04%)	- MRD positivity (either BM or serum) at 1 and 3 months associated with higher 3-year CIR and risk of death - $\geq 1.5$ -fold increase in ctDNA between 1 and 3 months post HCT associated with highest risk of relapse (HR=28.5; P=0.0001) and death (HR=17.4; P=0.0009)
<p>AML, acute myeloid leukemia; BM, bone marrow; CIR, cumulative incidence of relapse; CIR, cumulative incidence of relapse; CMML, chronic myelomonocytic leukemia; CR, complete remission; DFS, disease-free survival; <i>DTA</i>, DNMT3A, TET2, ASXL1; ESA, erythropoiesis-stimulating agent; FISH, fluorescence in situ hybridization; FLAMSA-Bu, fludarabine, cytarabine, amsacrine, busulfan; HCT, allogeneic hematopoietic cell transplantation; HMA, hypomethylating agent; HR, hazard ratio; LOD, limit of detection; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MDS-EB, MDS with excess blasts; MFC, multiparameter flow cytometry; MPN, myeloproliferative neoplasm; NGS, next generation sequencing; OR, odds ratio; OS, overall survival; PB, peripheral blood; RIC, reduced intensity conditioning; t-MN, therapy-related myeloid neoplasms; WES, whole exome sequencing.</p>					


791

792 **Table 2.**

Category	Defining criteria
<b>MRD<sub>CR</sub></b>	1. Complete cytogenetic response* or normal karyotype, <b>and</b> 2. Complete MRD response: Negative results (lower limit of detection at least 0.1%) in all MRD tests (NGS, MFC, PCR) that were used
<b>MRD<sub>LL</sub></b>	1. Complete cytogenetic response* or normal karyotype, <b>and</b> 2. Any MRD above the detection limit of the assay but below the level of 0.1%
<b>MRD<sup>+</sup></b>	1. Complete cytogenetic response* or normal karyotype, <b>and</b> 2. Any MRD tests positive $\geq 0.1\%$
<b>-DTA<sup>+/-</sup></b>	Used as an additional MRD test qualifier: e.g. MRD <sub>CR</sub> -DTA <sup>+</sup> ; MRD <sup>+</sup> -DTA <sup>-</sup>
<b>MFC-MRD<sup>-</sup></b>	1. MFC is used as a stand-alone test without other genetic or molecular tests 2. MFC-MRD negative: No detection of any leukemic clones by MFC (lower limit of detection 0.1%)
<b>MFC-MRD<sup>+</sup></b>	1. MFC is used as a stand-alone test without other genetic or molecular tests 2. MFC-MRD positive: Detection of leukemic clones by MFC with a frequency $\geq 0.1\%$
<b>MRD relapse</b>	1. Previous documentation of MRD <sub>CR</sub> , MRD <sub>LL</sub> or MFC-MRD <sup>-</sup> after treatment, <b>and</b> 2. MRD relapse confirmed in a second consecutive samples, <b>and</b> 3. Newly detected MRD <sup>+</sup> , <b>or</b> 4. Newly detected MFC-MRD <sup>+</sup> , <b>or</b> 5. $\geq 1 \log_{10}$ increase of VAF of previously detected DTA variants after day +100 of allogeneic HCT <sup>†</sup>
DTA, <i>DNMT3A</i> , <i>TET2</i> , <i>ASXL1</i> ; LL, low level of detection (<0.1%); HCT, hematopoietic cell transplantation; HI, hematologic improvement; MFC, multiparameter flow cytometry; MRD, measurable residual disease; VAF, variant allele frequency.	
*International Working Group 2023 response criteria (unchanged from IWG 2006). <sup>9</sup>	
†Corroboration by sorted donor chimerism analyses recommended.	

793

# Figure 1



Downloaded from <http://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2023010098> by guest on 08 August 2023

Figure 1.

Figure 2

● Hematopoietic stem cell    ● Leukemic stem cell    ● Transformed leukemic stem cell




Figure 2.

Downloaded from <http://ashpublications.org/hematology/article-pdf/doi/10.1182/bloodadvances.2023010098/2053607> by guest on 08 August 2023